Literature DB >> 8763875

Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.

P J Wood1, J M Sansom, I J Stratford, G E Adams, C Szabo, C Thiemermann, J R Vane.   

Abstract

The effect of the nitric oxide (NO) donor SIN-1 on energy metabolism was examined in three murine transplantable tumours in vivo using 31P MRS. SIN-1 at 2 mg kg-1 i.v. reduced Pi/total by 40-50% in SCCVII/Ha and KHT tumours within 5 min of injection, returning to control levels by 20 min. However, this dose of SIN-1 did not consistently alter Pi/total in RIF-1 tumours. Reduction in Pi/total in SCCVII/Ha tumours 10 min after 5 mg kg-1 i.v. SIN-1 was similar to that for 2 mg kg-1. SIN-1 at 10 mg kg-1 had no effect on Pi/total at 10 min after injection, but increased this ratio 2-fold over control at 60 min, at which time no effect of the lower doses of SIN-1 were observed. SIN-1 effects on SCCVII/Ha tumour response to X-rays were also examined, using an in vivo/in vitro clonogenic assay 24 h after treatment. SIN-1 at 0.5-2 mg kg-1 i.v. given immediately before irradiation increased tumour cell killing 2-4-fold over that for 15 Gy X-rays alone, while higher SIN-1 doses were ineffective. The results indicate that NO donors can alter tumour energy metabolism and X-ray response in a manner consistent with increased oxygenation. However, these responses are dependent upon dose, timing and tumour type.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763875      PMCID: PMC2149982     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  17 in total

1.  An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions.

Authors:  J E Thomson; A M Rauth
Journal:  Radiat Res       Date:  1974-05       Impact factor: 2.841

2.  Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency.

Authors:  J Sennesael; D Verbeelen; S Degré; P Unger; J C Stolear; J Ostrowski; H M von Hattingberg; W Gaertner
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1993-11

Review 3.  Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters.

Authors:  L J Ignarro
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

4.  Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors.

Authors:  J Kalmus; P Okunieff; P Vaupel
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

5.  Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine.

Authors:  W G Kaelin; S Shrivastav; R L Jirtle
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

6.  A new mouse tumor model system (RIF-1) for comparison of end-point studies.

Authors:  P R Twentyman; J M Brown; J W Gray; A J Franko; M A Scoles; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

7.  Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation.

Authors:  M R Horsman; D J Chaplin; J M Brown
Journal:  Radiat Res       Date:  1989-04       Impact factor: 2.841

8.  Endothelium-dependent vasodilatation in human epicardial coronary arteries: effect of prolonged exposure to glyceryl trinitrate or SIN-1.

Authors:  M Kuhn; U Förstermann
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

9.  Cinnarizine and flunarizine as radiation sensitisers in two murine tumours.

Authors:  P J Wood; D G Hirst
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

10.  Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Authors:  D G Hirst; J M Brown; J L Hazlehurst
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.